D4.4 Regulation action plan

The bioeconomy is a new market field that was not considered when most of the existing regula-tions were drafted in several areas, including, for example, regulations on the end-of-life (EOL) stage of plastics. Consequentially, even though an EU bioeconomy strategy exists, a coherent and coor-dinated policy framework is still missing1. In addition, the lack of necessary mechanisms (e.g. regu-lative carbon pricing) and the fact that existing policies and standards are mostly based only on fossil-based products (e.g. existing EOL schemes are focused on fossil-based products and do not consider bio-based counterparts) are hampering the development of the bioeconomy

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

D4.4 Regulation action plan

The bioeconomy is a new market field that was not considered when most of the existing regula-tions were drafted in several areas, including, for example, regulations on the end-of-life (EOL) stage of plastics. Consequentially, even though an EU bioeconomy strategy exists, a coherent and coor-dinated policy framework is still missing1. In addition, the lack of necessary mechanisms (e.g. regu-lative carbon pricing) and the fact that existing policies and standards are mostly based only on fossil-based products (e.g. existing EOL schemes are focused on fossil-based products and do not consider bio-based counterparts) are hampering the development of the bioeconomy

Technical design of the phase I Mu3e experiment

The Mu3e experiment aims to find or exclude the lepton flavour violating decay μ→eee at branching fractions above 10−16. A first phase of the experiment using an existing beamline at the Paul Scherrer Institute (PSI) is designed to reach a single event sensitivity of 2⋅10−15. We present an overview of all aspects of the technical design and expected performance of the phase I Mu3e detector. The high rate of up to 10(8) muon decays per second and the low momenta of the decay electrons and positrons pose a unique set of challenges, which we tackle using an ultra thin tracking detector based on high-voltage monolithic active pixel sensors combined with scintillating fibres and tiles for precise timing measurements.ISSN:0168-9002ISSN:1872-957